Intellect Neurosciences Inc. (fka ILNS)

[newtechinvestor]

Biotech Events and News in Year 2010
1. Phase III Studies in Alzheimer’s Disease

Healthcare investors will turn their focus to Alzheimer’s disease in 2010.

Any new drug that could potentially stop or even reverse the loss of memory and cognitive decline that makes Alzheimer’s such a devastating disease would be a mega-blockbuster. Actual sales estimates vary and are conditional on the efficacy and safety profile of the drug, but it’s not out of bounds to forecast a groundbreaking Alzheimer’s drug achieving peak sales of well over $10 billion, perhaps even $20 billion a year.

With stakes this high, pay attention to two high-profile phase III studies in Alzheimer’s scheduled to announce results next year:

Medivation and its global development partner Pfizer are putting the experimental Alzheimer’s drug Dimebon through a series of phase III clinical trials. The first of these pivotal studies, dubbed CONNECTION, in patients with mild to moderate Alzheimer’s should be ready to release top-line data in the second quarter.

Towards the end of 2010, Elan is expected to have data ready from a phase III study of its experimental Alzheimer’s drug bapineuzumab in patients who carry a gene, APoE4, thought to increase the risk of developing early, more aggressive disease.

Pfizer also co-owns rights to bapineuzumab due to its takeover over of Wyeth. More recently, Johnson & Johnson acquired a stake in Elan, including its Alzheimer’s drug research program, which gives it an important stake in the outcome of the bapineuzumab study.

http://www.beststocktips.net/biotech-events-and-news-in-2010.htmlhttp://www.beststocktips.net/biotech-events-and-news-in-2010.html